We report data from three patients with severe Pagetes disease of bone who were treated with mithramycin.
Introduction Though Paget's disease of bone may be asymptomatic and often limited to a small number of bones, there may be extensive skeletal involvement and severe bone pain. Treatment of the disorder with a high calcium and phosphate diet, vitamin D, parathyroidectomy, and fluoride have not proved uniformly satisfactory (Albright and Reifenstein, 1948; Albright and Henneman, 1955; Higgins et al., 1955; Avioli and Berman, 1968) . Calcitonin is at present being assessed in the treatment of Paget's disease of bone (Bijvoet et al., 1968) .
Mithramycin, an antibiotic derived from Streptomyces plicatus, has cytotoxic activities and has been used almost exclusively in the treatment of various tumours (Curreri and Ansfield, 1960; Parker et al., 1960; Kofman and Eisenstein (Goldberg, 1965; Yarbo et al., 1966) . Changes in calcium metabolism noted during mfithramycin therapy (Uacobse et al., 1965; Parsons-et al., 1967) resulted in its administration to two patients with Paget's disease of the bone. Relief of bone pain and -clear-cut effects on calcium and phosphorus metabolism occurred in these individuals (Ryan et al., 1969) .
We here report clinical and biochemical data on three patients with severe Paget's disease of bone who were treated with miithramycin
Patients and Methods Clinical and biochemical details of the patients investigated -are shown in the Table. Calcium and phosphorus balance studies were perfonned in all cases. Mithramycin 15,ug/kg of body weight dissolved in 500 ml of 5% dextrose was administered daily by means of an intravenous infusion which lasted four to five hours. A five-day period of treatnent with mithramycin alternated with a five-day period during which the drug was not given.
Balance study techniques and phosphate analysis have been reported (Walker and Collins, 1963 The fall in plasma calcium noted during mithramycin infusion is probably related to decreased bone resorption. This concept is supported by the pronounced fall in urinary hydroxyproline excretion which mainly reflects bone resorption rates. Ryan et al. (1969) suggested that mithramycin has a cytotoxic action on overactive or excess numbers of osteoclasts. These workers also noted a prompt reduction in urinary hyroxyproline excretion and postulated a direct action of mithramycin on osteoclasts. It is possible that the slow fall in plasma alkaline phosphatase also reflects a decline in osteoblastic activity secondary to decreased bone resorption. The fall in plasma calcium noted during mithramycin infusion returned to normal levels fairly rapidly, suggesting increased parathyroid hormone release. This is supported by a fall in plasma phosphate and increased phosphaturia in Cases 1 and 3. In Case 2 the plasma calcium did not rise above 9 mg/100 ml and there was no fall in plasma phosphate or increased phosphaturia. The probable explanation of these findings was that parathyroid hormone production was less in Case 2 than in Cases 1 and 3. In Cases 1 and 3 there was a fall in urinary and faecal calcium, either during or immediately after the mithramycin infusion. It is known that parathyroid hormone increases intestinal and renal tubular reabsorption of calcium (Kleeman et al., 1958; Bernstein et al., 1963) , so this may be the mechanism by which plasma calcium returns to normal values when bone resorption is inhibited by mithramycin.
The question arises whether the beneficial effect of mithramycin in Paget's disease of bone is due to direct inhibition of bone resorption by mithramycin or to the action of excess parathyroid hormone produced as a result of mithramycin-induced hypocalcaemia.
Parathyroid hormone normally increases bone destruction (Barnicot, 1948) , but in view of the fall in urinary hydroxyproline the destructive effect of parathyroid hormone on bone must in some way be inhibited by mithramycin. There is some evidence that parathyroid hormone also has an anabolic effect on bone, and Kalu et al. (1970) demonstrated a 23-5% increase in bone calcium, a 21% increase in stable hydroxyproline, and a 12-9% increase in incorporation of 3H-proline into bone hydroxyproline in thyroparathyroidectomized rats treated with parathyroid hormone. This anabolic effect of parathyroid hormone on bone may be of importance if its destructive effect is simultaneously blocked by mithramycin.
The metabolic effects of mithramycin on calcium and phosphorus metabolism appear to be similar to those of calcitonin, which is known to be of therapeutic use in Paget's disease of bone. Calcitonin, like mithramycin, inhibits bone resorption and reduces plasma calcium in patients with Paget's disease of bone (Bijvoet et al., 1968) . There is presumably increased production of parathyroid hormone secondary to calcitonin-induced hypocalcaemia, and it may well be that both mithramycin and calcitonin exert their beneficial effect in Paget's disease of bone by a similar mechanism. 
Patients and Methods
The salient features of the four patients treated are shown in Table I . The three women were postmenopausal; the other 
